Background: Aggressive mature B-cell non-Hodgkin's lymphomas (BCL) sharing features of Burkitt's lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) (intermediate BL/DLBCL) but deviating with respect to one or more characteristics are increasingly recognized. The limited knowledge about these biologically heterogeneous lymphomas hampers their assignment to a known entity, raising incertitude about optimal treatment approaches. We therefore searched for discriminative, prognostic, and predictive factors for their better characterization.
comprising among others, double-hit lymphomas with MYC aberration, with a particularly negative prognostic impact [2, 3] . From the clinical point of view, a major issue regarding this aggressive group of lymphomas is the lack of an optimal treatment approach, and all attempts to define the borders of intermediate BL/DLBCL with known diagnostic markers, such as CD10, MUM1, Bcl2, Bcl6 protein expression or FISH for BCL2, BCL6 and MYC, remained unsatisfactory so far [1, 3, 4] .
Therefore, the purpose of this study is to find additional diagnostic and predictive markers in order to further characterize aggressive mature BCL, with particular regard to intermediate BL/DLBCL. Based on the reported geneexpression profiling studies, which in the recent years were found to be an accurate method to distinguish BL from DLBCL, we analyzed the expression of three genes [chromosome segregation 1-like (CSE1L), inhibitor of DNA binding-3 (ID3), and signal transduction and transcription-3 (STAT3)] on a tissue micro array (TMA) [5, 6] .
CSE1L is implicated in the nuclear-to-cytoplasmic trafficking of importin-alpha relevant for the nuclear transport of several proliferation-associated proteins, oncogenes, and tumor suppressor genes, such as p53. Although CSE1L was shown to be overexpressed in various carcinomas [7] and melanomas [8] , few studies have reported high expression in high-grade B-NHL when compared with low-grade B-NHL [9] , primary cutaneous B-cell lymphomas [10] , or acute myeloid leukemias [11] . ID3 belongs to the inhibitor of DNA binding (ID) family of proteins which negatively regulate basic helix-loop-helix transcription factors known as E-proteins and control many aspects of lymphocyte proliferation, differentiation, and survival [12] . ID family proteins have been shown to be overexpressed in several solid tumors [13] ; however, very little is known about the role of ID3 in human lymphomas [14, 15] . Finally, STAT3 belongs to the signal transduction and transcription (STAT) family of transcription factors and binds to interleukin (IL)-6 and IL-10 responsive elements. In cell culture assays, both cytokines and STAT3 were shown to be expressed by non-germinal-center-B-cell (non-GCB)-derived DLBCL cells. Moreover, a signature of STAT3 target genes typifies a subset of non-GCB DLBCL tumor cells with high STAT3 protein levels [16] .
We investigated a cohort of 242 aggressive mature BCL for the expression of the mentioned markers CSE1L, ID3, and STAT3 on a TMA. Their diagnosis was initially established by morphology with the support of known immunophenotypical, and genetic markers. In a univariate analysis, all the three new markers were able to significantly discriminate BL from DLBCL, and their expression correlated with survival. Through computational analysis, we developed a new algorithm for aggressive mature BCL based on the combination of CSE1L and STAT3 expression with MYC rearrangement by FISH, which was superior in predicting the diagnosis of BL and DLBCL than previous marker combinations. Finally, the use of this algorithm appears to be of predictive value regarding the therapeutic response. Based on these data, we propose the use of these new markers as an additional diagnostic and predictive tool, which, however, needs to be analyzed prospectively on a larger number of cases before eventually being included in the routine diagnostic procedures.
patients and methods patients and biopsy specimen selection A total of 288 patients with aggressive mature BCL diagnosed from 1990 to 2009 at the Institute of Surgical Pathology, University Hospital Zurich as well as 10 BL cases derived from an affiliated hospital (Town Hospital Triemli) in Zurich were included in the study. Twenty-three additional BL or DLBCL cases collected during 2010 were used successively to validate the diagnostic algorithm. All lymphomas were reviewed independently by two pathologists (DS and MT) and diagnosed, according to the current WHO 2008 classification [1] as outlined in the supplementary data. DLBCL were further subclassified into GCB and non-GCB types, according to the Hans algorithm [17] .
This study was in accordance with Swiss laws and approved by the official authorities of the ethical committee of the Canton Zurich (StV2-2007).
treatment protocol
According to the first-line chemotherapy used after the histological diagnosis, four therapeutic groups were established (for details, see supplementary data). The 'first' group (89 patients) consisted of 'CHOPlike' regimens, the 'second' group (16 patients) consisted of 'intensive' regimens, the 'third' group (6 patients) comprised vincristine, adriamycin/ doxorubicin, cyclophosphamide, etoposide, and prednisone (VACOP), and the 'fourth' group (6 patients) comprised 'low-intensity' regimens chlorambucil and prednisolone [18] . Each group was further subclassified according to the use of rituximab.
immunohistochemistry
Based on gene-expression profiling [5, 6] , we searched for reported genes significantly overexpressed in either BL or DLBCL and selected the commercially available antibodies specific for CSE1L, ID3, and STAT3 which showed the best staining performance and reproducibility in normal and neoplastic lymphatic tissues. For antibodies used and their evaluation see supplementary Table S1 , available at Annals of Oncology online. Immunohistochemistry on 2.5-μm-thick TMA sections was carried out using a Ventana ES instrument (Roche's Ventana Medical Systems, Baar, Switzerland) according to the standard protocols.
western blotting
Protein extracts from human BL-derived Raji cells were subjected to Western blotting analysis. An anti-β-actin (mouse monoclonal, clone AC-15, code A5441, Sigma-Aldrich, Hamburg, Germany) antibody was used as a control for protein loading. (supplementary Figure S1 , available at Annals of Oncology online).
fluorescence in situ hybridization (FISH) FISH analysis was carried out as previously described [19, 20] Percentages were calculated on the basis of the number of cases with available information. The omission of cases without clinical information explains the difference in 'age at diagnosis' and 'gender' existing between Tables 1 and 2 . Percentages may not reach a total of 100 because of rounding. BL, Burkitt's lymphoma; DLBCL, diffuse large B-cell lymphoma.
original articles Annals of Oncology resulting decision trees were compared by their misclassification error of 100-fold bootstrapped cross-validation. The validation of the decision trees was carried out using a separate group of 23 new lymphomas, for which the same immunohistochemical and FISH analysis were carried out as in the initial cohort. This validation cohort was evaluated as before by a cytogeneticist (VM) and an assessor (CM) who were blinded to the diagnosis.
clinical data and survival analysis
The following patient characteristics were collected: age at diagnosis, gender, lymphoma site, and therapeutic strategy. The response to treatment and the occurrence of relapse or death was recorded. The Kaplan-Meier method was used to estimate overall (OS) and progression-free survival (PFS) (see supplementary data, available at Annals of Oncology online for definition).
The log-rank test, stratified by the diagnostic group, was used to compare the survival distributions. The differences between the strata were tested with the chi-square test. Tables 1 and 2. expression of CSE1L, ID3, and STAT3 in normal lymphatic tissues and in human BL-derived raji cells
The specificity of these antibodies was confirmed in a Western blot analysis (supplementary Figure S1 , available at Annals of Oncology online).
In non-neoplastic tissue, CSE1L and ID3 were predominantly expressed in GCB cells, whereas STAT3 was expressed in cells of the inter-follicular area (Figure 1) .
expression of CSE1L, ID3, and STAT3 in BL, DLBCL and intermediate BL/DLBCL
A univariate analysis revealed a statistically significant differential expression of CSE1L, ID3, and STAT3 in BL 
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versus DLBCL (Figure 1 ). CSE1L and ID3 were both found to be more frequently expressed in BL than in DLBCL (for both P < 0.001). STAT3, instead, was more frequently expressed in DLBCL (P < 0.001), in particular more often in the non-GCB than in the GCB subgroup (P < 0.001). For summary, see supplementary Table S3 , available at Annals of Oncology online.
survival analysis and correlation with marker expression
For 220 patients, follow-up was available. Twenty-nine percent of them relapsed and 23% of the patients had no disease-free interval (supplementary Table S4 , available at Annals of Oncology online).
Overall, univariate survival analysis showed that ID3-positive patients had significantly longer OS and PFS than ID3-negative patients (P = 0.020, with 5-year OS of 63.5% versus 44.7%; P = 0.033, with 5-year PFS of 56.3% versus 36.8%), and CSE1L expression was associated with longer PFS (P = 0.044, with 5-year PFS of 61.0% versus 40.1%). Finally, considering only the group of DLBCL, the expression of STAT3 was associated with longer OS (P = 0.052, with 5-year OS of 53.0% versus 38.4%) and PFS (P = 0.023; with 5-year PFS of 44.7% versus 30.7%). Neither OS (P = 0.920) nor PFS (P = 0.796) differed in GCB versus non-GCB assessed by Hans classifier.
diagnostic classifiers for BL and DLBCL
In order to evaluate whether the 'combined' expression of CSE1L, ID3, and STAT3 enhances diagnostic precision, we made use of binary decision trees to predict diagnosis. As this computational approach is based on a binary system, the group of insufficiently defined intermediate BL/DLBCL was omitted, and decision trees were trained to predict the diagnosis of either BL or DLBCL. Different combination sets with the expression of new markers, CSE1L, ID3, and STAT3, of conventional markers (CD10, MUM1, Bcl-2, and Bcl-6), as well as FISH results for BCL2, BCL6 and MYC translocations were introduced into the algorithm, which in turn selected the markers to build the best decision trees, also called classifiers (Figure 2) .
From all different combinations of datasets applied, the algorithm selected STAT3 and CSE1L expression, as well as MYC translocation to build the decision tree with the highest performance. This decision tree, which we called 'new classifier', showed the lowest misclassification error of 8.7% [standard deviation (SD) = 5.6% in 100-fold bootstrapped cross-validation with a random level of 50.0% as balanced error] (see Figure 3 for all different classifiers).
validation of the new classifier
The validation of a predictive decision tree must be carried out using a different set of cases than the ones used for their training, and consists in the comparison of the original diagnosis with the one predicted by the decision tree. For this purpose, 23 additional aggressive mature BCL cases (5 BL and 18 DLBCL) recently diagnosed at the University Hospital Zurich were employed. The 'new classifier' predicted a correct diagnosis in all BL and DLBCL cases, with a sensitivity and specificity of 100% (see supplementary Table S5 , available at Annals of Oncology online).
impact of the new classifier on diagnosis and prognosis, in particular for the intermediate BL/ DLBCL group of lymphomas
We first added the whole cohort with all three lymphoma types including intermediate BL/DLBCLs to the training set, as the Figure 2 . Decision trees trained to predict the diagnosis of either Burkitt's lymphoma (BL) or diffuse large B-cell lymphoma (DLBCL) with different sets of markers and FISH results (n = 248). The 'conventional classifier without FISH data' resulted when all conventional markers (CD10, MUM1, Bcl-2, and Bcl-6) were submitted to the algorithm. When the FISH data (BCL2, BCL6, and MYC translocations) were in addition applied, the algorithm chose the expression of CD10 and the data of FISH for MYC to build the 'conventional classifier with FISH data'. When the expression of new markers CSE1L, inhibitor of DNA binding-3 (ID3), and signal transduction and transcription-3 (STAT3) as well as conventional markers were submitted to the binary decision tree, only two new markers CSE1L and STAT3 were selected to build an algorithm, called 'classifier without FISH data'. Finally, the decision tree with the highest performance resulted when all (conventional and new) markers in addition to FISH data were applied. This 'new classifier' was composed of the data of the expression of CSE1L and STAT3 and of the FISH data for MYC.
original articles Annals of Oncology latter were excluded from the initial set. Over the whole cohort, six DLBCL cases were reclassified as predicted BL ( pBL) and two BL cases as predicted DLBCL ( pDLBCL). By running the 'new classifier' over the intermediate BL/DLBCL group only, 13/27 lymphomas were predicted as BL ( pBL) and 14/27 as DLBCL ( pDLBCL). Interestingly, none of the pBL cases showed MUM1 expression, in contrast to four positive (28.6%) pDLBCL cases. GCB phenotype was present in 12/13 (92.3%) pBL cases and 10/14 (71.4%) pDLBCL cases. All pBL carried a MYC translocation (in contrast to 6/14 pDLBCL) and seven of them presented with a simple karyotype (only 1/14 pDLBCL). Both the groups presented five cases with triple or double hits each. Finally, STAT3 expression was more frequent in the pDLBCL (71.4%) than in the pBL (7.7%) group.
We next analyzed the influence of the new classifier on prognosis. We compared OS and PFS of predicted groups receiving an intensive therapy versus CHOP-like therapy with or without rituximab, as these two therapeutic groups represented >90% of all therapeutic approaches in our cohort.
Regarding all lymphoma subtypes, the 'new classifier' identified patients with pBL showing a significantly longer cumulative OS and PFS when treated with intensive therapy than pBL treated with CHOP-like therapy, with or without rituximab (P = 0.015 and P = 0.007, respectively) ( Figure 4A ). When the predicted diagnoses were compared with the initial ones, the prognosis for 4/6 pBL patients initially diagnosed as DLBCL was dismal (no disease-free interval and disease-related death occurring 0.5, 1.2, 1.8, and 13.9 months after diagnosis). The therapeutic approach was known in one case (R-CHOP, 1.2 months survival). The remaining 2 pBL recurred after 22.56 and 77.5 months, respectively, and were treated with R-CHOP chemotherapy. The two cases reclassified as pDLBCL, originally diagnosed as BL, had an indolent course (recurrence after 81 months, no recurrence after 192 months). Of note, reclassified lymphomas presented with features otherwise indistinguishable from the rest of the original diagnostic group.
Finally, the predictive value of the 'new classifier' was also evident when applied to the intermediate BL/DLBCL. In particular, the 'new classifier' was able to predict a significantly longer OS and PFS in pBL treated with intensive regimen compared with pBL treated with CHOP-like regimens, with or without rituximab (P = 0.040 for both OS and PFS, clinical data available for 14 patients,) ( Figure 4B ).
discussion
In this report, we present three immunohistochemical markers (CSE1, ID3, and STAT3) differentially expressed in BL and DLBCL as well as a new decision tree, comprising the protein expression of CSE1, STAT3, and MYC translocation, which enables improved segregation of BL from DLBCL, and of intermediate BL/DLBCL into two different prognostic groups. CSE1L and ID3 were more frequently expressed in BL. In contrast, STAT3 expression was associated with DLBCL, especially the non-GCB subgroup. As expected, our findings correlate with the increased transcription levels previously reported in gene-expression studies [5, 6] . Moreover, we could confirm previous reports of STAT3 overexpression in non-GCB-type DLBCL, both in a small series of primary lymphomas and in cell lines [16, 22] . Increased CSE1L expression has also been reported in highly proliferating lymphomas, including DLBCL, and a gain of the gene locus was reported in primary cutaneous B-cell lymphomas. In the case of ID3, a very limited data are available about its expression and potential role in lymphomas [9, 10, 14, 15] .
Although the entity of BL is well characterized, its distinction from DLBCL is not always unequivocal. In order to improve the diagnostic accuracy of these entities, predictive models were trained with different predictor sets (traditional and new markers, FISH data) and cross-validated in 100-fold bootstrapping, with the diagnosis of BL or DLBCL, representing the prediction targets. The algorithm with highest discriminative capacity comprised STAT3, CSE1L, and MYC translocation. This algorithm, called 'new classifier', demonstrates the lowest misclassification error for the distinction of BL versus DLBCL when applied to the whole cohort (Figures 2 and 3) . The validation of the proposed predictive model on 23 recently diagnosed aggressive mature Figure 3 . Performance of the decision trees. Performance of the decision trees is based on the misclassification error (0%-100%). The misclassification error is lowered by adding the new markers to the conventional markers as indicated in Figure 2 . This holds true for strategies including FISH or not (A = conventional classifier without FISH data, B = classifier without FISH data, C = conventional classifier with FISH, and D = new classifier). Statistical significance is given for two of the three markers: P values from left to right for the differences between the two adjacent markers: P = 2.8e−20 (difference A to B), P = 4.4e−10 (difference B to C), P = 0.12 (difference C to D) (calculated with Welch's two sample t-test).
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BCL on the whole tissue sections displays a high agreement with the results obtained on the TMA. Of note, the classifier appears superior in instances where FISH is unavailable (Figure 3 ).
Most interestingly, the 'new classifier' emerged as the only algorithm with the predictive value for all lymphomas. Notably, when the 'new classifier' was applied to the whole cohort including the intermediate BL/DLBCL group, it predicted a more favorable outcome in patients identified as pBL if treated with intensive therapy rather than the CHOPlike regimen (Figure 4 ). The 'new classifier' presented seems therefore to be very promising in identifying patients who might benefit from high-dose chemotherapy regimens. This stratification into groups of patients responding to intensive chemotherapy appears particularly meaningful for two reasons. First, no standardized treatment recommendations exist for patients diagnosed as intermediate BL/DBCL. In particular, recent studies showed a certain benefit for BL-oriented therapies, but not for DLBCL-oriented R-CHOP regimens, in patients with double-hit lymphomas with concurrent BCL2 and MYC translocations [23, 24] . However, as the group of intermediate BL/DLBCLs includes also cases which might not require an intensive therapy [24] , the identification of pDLBCL cases will allow a more individualized therapeutic approach even in patients with lymphomas with biological overlap. Second, as shown by the few DLBCLs identified as pBLs, some cases presenting with characteristic features of DLBCL carry a very aggressive course and might require an intensive therapy. Their identification was not possible with conventional methods, but with the proposed 'new classifier'. Hence, the additional, predictive approach to lymphomas by the 'new classifier' might open new horizons in treatment planning and allows affronting biologically overlapping lymphomas in an alternative than the mere cell-of-origin-based way.
The validity of our study population is evidenced by the significantly better OS and PFS of patients with an initial diagnosis of BL than those with DLBCL, whereas patients diagnosed as intermediate BL/DLBCL showed the poorest outcome as reported in the literature (data not shown) [23, 24] .
Recent studies have suggested a potential role for CSE1L, STAT3, and ID3 in oncology drug development. CSE1L overexpression was shown to enhance apoptosis induced by certain chemotherapeutic drugs [25, 26] . For ID3, a number of studies in solid tumors suggest a role as a putative target [27] [28] [29] . STAT3 has been proposed as a putative therapeutic target, either indirectly by proteasome inhibitors (e.g. bortezomib) and histone deacetylase inhibitors, or as a direct molecular target of drugs currently under development [30, 31] .
In summary, we present a new algorithm, which beyond its diagnostic potency, bears predictive potential to treatment response allowing tailored therapeutic approaches, in particular for patients with intermediate BL/DLBCLs. Moreover, the markers presented in this article represent easily detectable molecules. Altogether, we believe that these data merit confirmation by prospective studies on larger cohorts.
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